Literature DB >> 2934558

Surgical management of popliteal aneurysms. Trends in presentation, treatment, and results from 1952 to 1984.

G E Anton, N R Hertzer, E G Beven, P J O'Hara, L P Krajewski.   

Abstract

Graft replacement was performed for 123 (77%) of 160 popliteal aneurysms evaluated at The Cleveland Clinic from 1952 to 1984, employing autogenous saphenous vein in 58 (36%), polytetrafluoroethylene in 19 (12%), and of historic interest, Dacron (12%) or arterial homograft (16%) in 46. The 10-year cumulative patency (CP) rate was 56% and the limb salvage (LS) rate was 83% following graft replacement, but late results were superior in patients who received vein bypass (CP, 94%; LS, 98%), in those who underwent revascularization before ischemic complications had occurred (CP, 92%; LS, 96%), and in those who recovered both pedal pulses (CP, 64%; LS, 96%). Long-term asymptomatic limbs were restored in 96%, 92%, and 89% of these subsets, respectively, compared with 65% of those receiving other graft materials (p = 0.00003), 59% of those with preoperative ischemic symptoms (p = 0.00001) and 68% of those regaining only an isolated popliteal pulse (p = 0.0326). These data indicate that popliteal aneurysms should be corrected by vein bypass to a patent tibioperoneal segment before spontaneous thrombosis or embolization eliminates the critical outflow bed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2934558

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  2 in total

1.  Implementation of a successful endovascular surgical program in a non-teaching tertiary-care centre in Ontario.

Authors:  Rod P N Willoughby; John A Fenton; Santosh R Pudupakkam; Robert A Greco; Evan W D Roberts; Guy DeRose; Stewart Kribs
Journal:  Can J Surg       Date:  2004-06       Impact factor: 2.089

2.  The management of popliteal aneurysm: the importance of early surgical repair.

Authors:  A W Halliday; P R Taylor; J H Wolfe; A O Mansfield
Journal:  Ann R Coll Surg Engl       Date:  1991-07       Impact factor: 1.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.